117 related articles for article (PubMed ID: 29788570)
1. HER2 status is an important biomarker in guiding personalized HER2 therapy.
Carney WP
Per Med; 2005 Nov; 2(4):317-324. PubMed ID: 29788570
[TBL] [Abstract][Full Text] [Related]
2. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
Morgan S; Amemiya Y; Slodkowska E; Lu FI; Parra-Herran C; Nofech-Mozes S; Trudeau M; Olkhov-Mitsel E; Seth A; Hanna WM
Anticancer Res; 2019 Oct; 39(10):5345-5352. PubMed ID: 31570428
[TBL] [Abstract][Full Text] [Related]
4. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
6. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
7. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
Fabi A; Malaguti P; Vari S; Cognetti F
J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
[TBL] [Abstract][Full Text] [Related]
9. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
11. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
Huang Y; Burns DJ; Rich BE; MacNeil IA; Dandapat A; Soltani SM; Myhre S; Sullivan BF; Lange CA; Furcht LT; Laing LG
BMC Cancer; 2017 Mar; 17(1):199. PubMed ID: 28302091
[TBL] [Abstract][Full Text] [Related]
12. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
13. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
14. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Carney WP
Expert Rev Mol Diagn; 2007 May; 7(3):309-19. PubMed ID: 17489737
[TBL] [Abstract][Full Text] [Related]
15. Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?
Carney WP; Bernhardt D; Jasani B
Biomark Cancer; 2013 Aug; 5():31-9. PubMed ID: 24179396
[TBL] [Abstract][Full Text] [Related]
16. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
17. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.
Ma L; Yang HY; Han XH; Li J; Wang F; Zhang CL; Yao JR; Shi YK
Chin Med J (Engl); 2012 Nov; 125(22):4104-10. PubMed ID: 23158151
[TBL] [Abstract][Full Text] [Related]
18. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
19. Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission.
Haq R; Gulasingam P
Curr Oncol; 2016 Apr; 23(2):91-5. PubMed ID: 27122973
[TBL] [Abstract][Full Text] [Related]
20. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
